New Stock News | Zhengxiang Pharmaceutical Submits Application to Hong Kong Stock Exchange Again

According to the Hong Kong Stock Exchange's disclosure on August 26, Zhengxiang Pharmaceutical (Nanjing) Group Co., Ltd. (referred to as: Zhengxiang Pharmaceutical) has submitted its listing application to the main board of the Hong Kong Stock Exchange, with CICC as the sole sponsor. The company previously submitted a listing application to the Hong Kong Stock Exchange on January 30, 2026. The prospectus shows that Zhengxiang Pharmaceutical is a commercial-stage biopharmaceutical company dedicated to the research and commercialization of innovative therapies to meet the medical needs in the fields of viral infectious diseases, oncology, and inflammatory diseases, where existing treatment options are limited. The companys core product, Marzylorase Tablets, is an inhibitor targeting the polymerase acidic protein ("PA") endonuclease of the influenza virus, which received approval from the National Medical Products Administration ("NMPA") for a New Drug Application ("NDA") for the treatment of adult influenza in July 2025, and subsequently in June 2026 received approval for the treatment of adolescent patients; the company is also developing influenza prevention solutions for populations exposed to the virus.